Ormeloxifene
![]() | |
Clinical data | |
---|---|
Trade names | Centron, Novex-DS, Saheli, Sevista, Chhaya |
Other names | Centchroman |
Routes of administration | By mouth |
Drug class | Selective estrogen receptor modulator |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 7 days |
Identifiers | |
| |
JSmol) | |
| |
| |
![]() ![]() |
Ormeloxifene | |
---|---|
Background | |
Type | Antiestrogen |
First use | 1991 |
Failure rates (first year) | |
Perfect use | 2% |
Typical use | 9% |
Usage | |
Duration effect | One week |
Reversibility | Immediate |
User reminders | Taken twice weekly for first 13 weeks |
Clinic review | Annually |
Advantages and disadvantages | |
Delayed menstruation | |
Medical notes | |
Only approved as a contraceptive in India |
Ormeloxifene, also known as centchroman, is one of the
Ormeloxifene has also been licensed under the trade names Ormalin, Novex-DS, Centron, and Sevista.
Medical uses
Ormeloxifene is primarily used as a contraceptive but may also be effective for
Birth control
Ormeloxifene may be used as a weekly oral contraceptive.[6] The weekly schedule is an advantage for women who prefer an oral contraceptive, but find it difficult or impractical to adhere to a daily schedule required by other oral contraceptives.
For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week.[6] From the thirteenth week on, it is taken once per week.[6][7] The consensus is that backup protection in the first month is a cautious but sensible choice. A standard dose is 30 mg weekly, but 60 mg loading doses can reduce pregnancy rates by 38%.[8]
It has a failure rate of about 1-2% with ideal use which is slightly less effective than found for combined oral contraceptive pills.[9]
Other indications
- Ormeloxifene has also been tested in experimental setting as a treatment for menorrhagia.[10]
- use in treatment of mastalgia and fibroadenoma has also been described.[11]
Side effects
There are concerns that ormeloxifene may cause
Pharmacology
Ormeloxifene is a selective estrogen receptor modulator (SERM). In some parts of the body, its action is estrogenic (e.g., bones), in other parts of the body, its action is antiestrogenic (e.g., uterus, breasts).[13][14][15] It causes an asynchrony in the menstrual cycle between ovulation and the development of the uterine lining, although its exact mode of action is not well defined. In clinical trials, it caused ovulation to occur later than it normally would in some women,[9] but did not affect ovulation in the majority of women, while causing the lining of the uterus to build more slowly. It speeds the transport of any fertilized egg through the fallopian tubes more quickly than is normal.[9] Presumably, this combination of effects creates an environment such that if fertilization occurs, implantation will not be possible.[9]
History
Ormeloxifene was first discovered by Central Drug Research Institute (CDRI) in Lucknow, India.[13][16] Ormeloxifene was marketed in Delhi in July 1991 and in India in 1992, under the brand names Saheli and Choice-7.[9][17]
Since 2018, Centchroman is provided free-of-cost to the women in India by the government under the brand name Chhaya.[4][18][19][20]
Society and culture
Marketing
As of 2009, ormeloxifene was legally available only in India.[21]
Ormeloxifene has been tested and licensed as a form of birth control, as well as a treatment for dysfunctional uterine bleeding.
- manufactured by Torrent Pharmaceuticals, and marketed as birth control under the trade name Centron. Centron was discontinued.
- A new license for ormeloxifene was issued to Hindustan Latex Ltd., which now manufactures ormeloxifene as birth control under the trade names Saheli, Novex, and Novex-DS.
- Torrent Pharmaceuticals has resumed manufacture of ormeloxifene under the trade name Sevista, as a treatment for dysfunctional uterine bleeding.
See also
References
- PMID 8585887.
- PMID 18675966.
- ^ "HLL - Product Overview". Archived from the original on 1 November 2018.
- ^ a b "Chhaya". Centre for Health Informatics (CHI) of the National Health Portal (NHP), by the Ministry of Health and Family Welfare (MoHFW). Government of India. Archived from the original on 11 May 2021. Retrieved 29 June 2020.
- ^ "Contraception and women's empowerment: Here's how safe, reliable contraceptives are freeing women to earn". Hindustan Times. 10 July 2018. Retrieved 29 June 2020.
- ^ PMID 20227542.
- ^ "Home | ReproLinePlus".
- PMID 11257249.
- ^ S2CID 37474826.
- S2CID 39172838.
- S2CID 22828570.
- S2CID 23585991.
- ^ a b "CSIR-CDRI | Home". cdri.res.in. Retrieved 29 June 2020.
- ^ Kumar GR, Rituraj K, Hemant BK, Singh MM (November 2007). In-vitro anti-cancer breast activity of ormeloxifene is mediated via induction of apoptosis and autophagy. 37th annual conference of the endocrine society of India. Vol. 30. p. 35.
- PMID 18279897.
- ^ "Centchroman". CSIR-CDRI. Archived from the original on 14 February 2019. Retrieved 25 September 2018.
- PMID 20227542.
- ^ "परिवार नियोजन विधियों में छाया से अधिक अंतरा में बढ़ी महिलाओं की दिलचस्पी, जानिये इनके बारे में". Patrika News (in Hindi). 22 May 2018. Retrieved 29 June 2020.
- ^ Bhatia I (7 April 2018). "antara chhaya: Two months after launch, Antara, Chhaya contraceptives get good response from locals". The Times of India. Retrieved 29 June 2020.
- ISSN 0971-751X. Retrieved 29 June 2020.
- ISBN 978-81-8356-388-8.
Further reading
- Ray S, Grover PK, Kamboj VP, Setty BS, Kar AB, Anand N (February 1976). "Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and -chromans". Journal of Medicinal Chemistry. 19 (2): 276–279. PMID 1249807.
External links
- United States National Library of Medicine Centchroman entry in the Medical Subject Headings (MeSH) database
- Reproductive Health Online, a Johns Hopkins University affiliate providing information on Centchroman
- Central Drug Research Institute Archived 5 August 2016 at the R&Don Centchroman as birth control.
- Ministry of Health and Family Welfare - Indian government site; information about availability of Saheli.